.....what just happened to rhortons944 post on "Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis" ?
In simple terms ruxolitinib does not delay clonal evolution of cancer, even while masking disease-related symptoms meaning it's actually masking the cancer's progression and lessens detection of the cancer's advancement. This IS alarming considering the FDA is behind such a drug
Most damming evidence against the use of ruxolitinib to date.
in simple terms ruxolitinib does not delay clonal evolution of cancer, even while masking disease-related symptoms meaning it's actually masking the cancer's progression and lessens detection of the cancer's advancement. This IS alarming considering the FDA is behind such a drug.
...to date Irish has reported her husband John has had a functional cure in that his cancer has been in remission over 17 months now with disease modifying effects; Irishtrader52 posted Tues. Sep 2, 2014 7:26 PM "Imetelstat cleared fibrosis in marrow and that is disease modification and best measure of disease progression or not. More predictive than any blood chemistry as endpoint. Essentially a chemical bone marrow transplant as I see it. Exceeding life expectancy (LE) in IST MF trial is very close to meeting that new endpoint for Phase III). John is 17 months on Imetelstat and doing great. He exceeds his intermediate high risk LE at approximately 24 months. You could argue he already exceeded LE given his date of diagnosis rather than treatment start date as LE baseline. He by no means is alone."
I'll soon be able to afford a Tesla
no more gas pumps
no more carbon footprint
no more dirty environmentalist's looks
Tesla, the I-pod of the auto industry
furthermore the long term descending line of resistance has disappeared as of yesterday meaning the $2.68 200SMA should easily be taken out. How high we go depends on 30 million shorts covering. Here's to strong abstract data support next week forcing their hand.
I year ago pre ASH we were @ $3.66
I'm a true believer of critter karma. A Chipmunk in these shark infested waters better be a quick swimmer.
ruxolitinib is obviously a failure and the only hope for it is to find combos therapies with some sort of appearance of longer term symptomatic relief. OR JUST BRING IMETELSTAT OUT OF FDA JAIL HOLD and start curing cancer for godot's sake.
"Despite its dramatic symptomatic improvement and the suggestion of survival prolongation, there is no clear indication of a disease-modifying effect of ruxolitinib. Besides, at 3 years, 60% of patients are off treatment.51 Therefore, further efforts are necessary to improve ruxolitinib results. This is currently being attempted by combination with anemia-alleviating drugs or with agents aimed at achieving deeper disease-modifying effect (Table 2). Other JAK inhibitors that selectively suppress the clonal cells and restore normal hematopoiesis need to be developed"
Hairy go sit on the potty...you're full of it.
...maybe he forgot to change his diving mask for his racing helmet. One too many hats to coordinate. Gern's the only underwater stock on the bio board. Imagine if we had a red market day?
....racing the Geron sponsored porch, driving at break neck speed, heading to the FDA approval finish line.
Wait a minute here...did someone forget to fill the gas tank?
30 million HF shorts got a clear message from Scarlet during the CC's. Unless he surprises us with a data update or phase II announcement I'm beginning to think GERN will slowly trade up to it's June 12 partial release value of $3.00. Shorts don't appear in any rush to cover yet and data wont be known till ASH.
"Geron management is not sitting on its laurels" it's actually sitting on a porch, holding info sessions on honing sport car racing skills for managing biotech companies. $7 a session/ attendee. Potential $billions here fellow critters.